COCH
Envoy Medical, Inc.NASDAQHealthcare$0.70-5.69%ClosedMarket Cap: $14.7M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.17
P/S
60.85
EV/EBITDA
-0.54
DCF Value
$0.03
FCF Yield
-125.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-262.7%
Operating Margin
-9240.7%
Net Margin
-9857.3%
ROE
129.5%
ROA
-277.6%
ROIC
786.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $75.0K | -181.3% | $-6.4M | $-6.6M | $-0.27 | — |
| FY 2025 | $241.0K | -262.7% | $-22.3M | $-23.8M | $-1.23 | — |
| Q3 2025 | $42.0K | -383.3% | $-5.7M | $-6.5M | $-0.35 | — |
| Q2 2025 | $78.0K | -200.0% | $-5.1M | $-5.7M | $-0.32 | — |
| Q1 2025 | $46.0K | -391.3% | $-5.1M | $-5.0M | $-0.29 | — |
| Q4 2024 | $42.0K | -273.8% | $-4.5M | $-4.6M | $-0.36 | — |
| FY 2024 | $225.0K | -229.8% | $-19.3M | $-20.8M | $-1.49 | — |
| Q3 2024 | $56.0K | -233.9% | $-5.0M | $-6.0M | $-0.37 | — |
| Q2 2024 | $68.0K | -260.3% | $-4.9M | $-3.9M | $-0.27 | — |
| Q1 2024 | $59.0K | -159.3% | $-4.9M | $-6.3M | $-0.41 | — |
| Q4 2023 | $95.0K | -146.3% | $-6.7M | $-4.9M | $-0.25 | — |
| FY 2023 | $316.0K | -149.7% | $-18.4M | $-29.9M | $-2.54 | — |